Advancements in Immunotherapy for Lung Cancer: A Meta‐Analysis of Clinical Trial Outcomes
The Clinical Respiratory Journal · 2026-09 · 20 (9)
DOI: 10.1111/crj.70223 ↗Kurz gefasst
Metaanalyse in der Zeitschrift The Clinical Respiratory Journal, online erschienen am 09.09.2026. Verfasst von Yingjie Jiao und 1 weiteren Autor:innen. Beteiligte Einrichtung: Boshan Shantou Health Center, Zibo, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Immune Checkpoint Inhibitors, Immunotherapy, Lung Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Immune checkpoint inhibitors (ICIs) have changed therapeutic selections for advanced non–small cell lung cancer (NSCLC). However, comparative evidence versus chemotherapy through ICI monotherapy and chemo‐immunotherapy combination strategies remains incomplete. For this purpose, we conducted a meta‐analysis of randomized controlled trials (RCTs) to measure overall survival (OS) and progression‐free survival (PFS) outcome improvements in ICI monotherapy or ICI‐chemotherapy combined treatment. These interventions take place in adults (≥ 18 years) with advanced/metastatic NSCLC. The Preferred Reporting Items for Systematic Reviews and Meta‐Analyses directions were obeyed. PubMed, Scopus, and Web of Science were searched (2021–2024) for RCTs. A total of 7849 articles were retrieved. RCTs ( n = 17) qualify inclusion. Hazard ratios (HRs) along with 95% confidence intervals (CIs) for OS and PFS were pooled using random‐effects models. The heterogeneity was assessed by I 2 . Risk of bias was valued with RoB 2. Publication bias and leave‐one‐out sensitivity analyses were also estimated. ICI monotherapy RCTs ( n = 5) significantly enhanced OS (pooled HR = 0.73, 95% CI: 0.64–0.85; p < 0.0001) and PFS (pooled HR = 0.69, 95% CI: 0.49–0.96) with increased heterogeneity ( I 2 = 90%). Combined ICI‐chemotherapy RCTs ( n = 12) produced great benefits, with a pooled OS (HR = 0.68, 95% CI: 0.61–0.75; p < 0.00001; I 2 = 48%) and pooled PFS (HR = 0.55, 95% CI: 0.50–0.61; p < 0.00001; I 2 = 56%). Subgroup analyses proposed durable effects in smaller trials and with pembrolizumab‐based treatments. Risk‐of‐bias valuations underlined concern, primarily for deviations from therapeutic interventions. Sensitivity analyses set robustness, whereas publication bias was limited. ICI‐based remedies, especially chemo‐immunotherapy, significantly improve OS and PFS. Heterogeneity and experimental‐level bias warrant cautious interpretation. Hence, large RCTs are important to choose the best treatment possibility.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Boshan Shantou Health Center, Zibo, China.
- Department of Cadiothoracic Surgery, Zibo First Hospital, Zibo, China.
ORCID-Profile: Yan Zhao
Zitieren
APA
Jiao, Y., & Zhao, Y. (2026). Advancements in Immunotherapy for Lung Cancer: A Meta‐Analysis of Clinical Trial Outcomes. The Clinical Respiratory Journal, 20(9). https://doi.org/10.1111/crj.70223
Vancouver
Jiao Y, Zhao Y. Advancements in Immunotherapy for Lung Cancer: A Meta‐Analysis of Clinical Trial Outcomes. The Clinical Respiratory Journal. 2026;20(9). doi:10.1111/crj.70223
BibTeX
@article{Jiao2026,
author = {Jiao, Yingjie and Zhao, Yan},
title = {Advancements in Immunotherapy for Lung Cancer: A Meta‐Analysis of Clinical Trial Outcomes},
journal = {The Clinical Respiratory Journal},
year = {2026},
volume = {20},
number = {9},
doi = {10.1111/crj.70223}
}
EUVIMED